Skip to main content
SpringerLink
Log in

Prescribed Activity for Radioiodine Ablation

  • Chapter
Thyroid Cancer

Abstract

Radioiodine or remnant ablation refers to the destruction of residual macroscopically normal thyroid tissue in the thyroid bed after near-total thyroidectomy in patients with well-differentiated thyroid carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 339.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447–1463.

    Article  PubMed  CAS  Google Scholar 

  2. Wartofsky L, Sherman SI, Gopal J, et al. Therapeutic Controversy: The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998; 83:4195–4203.

    Article  PubMed  CAS  Google Scholar 

  3. Klain M, Ricard M, Leboulleux S, et al. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med 2002; 29(Suppl 2):S479–S485.

    Article  CAS  Google Scholar 

  4. Nemec J, Rohling S, Zamarazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979; 20:92–97.

    PubMed  CAS  Google Scholar 

  5. Balachandran S, Sayle BA. Value of thyroid carcinoma imaging after therapeutic doses of radioiodine. Clin Nucl Med 1981; 6:162–167.

    Article  PubMed  CAS  Google Scholar 

  6. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of post treatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:629–634.

    Article  PubMed  CAS  Google Scholar 

  7. Spies WG, Wojtowicz CH, Spies SM, et al. Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 1989; 14:793–800.

    Article  PubMed  CAS  Google Scholar 

  8. Fatourechi V, Hay ID, Mullan BP, et al. Are post therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10:573–577.

    Article  PubMed  CAS  Google Scholar 

  9. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80:1488–1492.

    Article  PubMed  CAS  Google Scholar 

  10. Sugg Sl, Ezzat S, Rosen IB, et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 1998; 83:4116–4122.

    Article  PubMed  CAS  Google Scholar 

  11. Sawka AM, Thephamongkhol K, Brouwers M, et al. A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668–3676.

    Article  PubMed  CAS  Google Scholar 

  12. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev 1994; 15:500–515.

    Article  PubMed  CAS  Google Scholar 

  13. Heufelder AE, Gorman CA. Radioiodine therapy in the treatment of differentiated thyroid cancer: Guidelines and considerations. Endocrinologist 1991; 1:273–280.

    Google Scholar 

  14. Samaan NA, Schultz PN, Hickey RD, et al. The results of various modalities of treatment of well-differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75:714–720.

    Article  PubMed  CAS  Google Scholar 

  15. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1980 though 1989. Surgery 1993; 114:1050–1058.

    PubMed  CAS  Google Scholar 

  16. DeGroot KJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414–424.

    Article  PubMed  CAS  Google Scholar 

  17. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.

    Article  PubMed  CAS  Google Scholar 

  18. Mazzaferri EL. Thyroid remnant 131-I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7:265–271.

    PubMed  CAS  Google Scholar 

  19. Hay ID, Grant CS, Van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed on a 50-year period. Surgery 1992; 112:1139–1147.

    PubMed  CAS  Google Scholar 

  20. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 104:1063–1075.

    Google Scholar 

  21. Mazzaferri EL, Young RI, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977; 56:171–196.

    Article  PubMed  CAS  Google Scholar 

  22. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982–992.

    Article  PubMed  CAS  Google Scholar 

  23. Tsang TW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82:375–388.

    Article  PubMed  CAS  Google Scholar 

  24. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19:545–576.

    PubMed  CAS  Google Scholar 

  25. Grebe SKG, Hay ID. Follicular cell-derived thyroid carcinomas. In Arnold A, editor. Endocrine Neoplasm. Kluwer Academic Publishers, 1997:91–140.

    Google Scholar 

  26. Beierwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J Nucl Med 1984; 25:1287–1293.

    PubMed  CAS  Google Scholar 

  27. Arad E, Flannery K, Wilson GA, O’Mara R. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants. Clin Nuc Med 1990; 10:676–677.

    Google Scholar 

  28. Atkins F, Van Nostrand D, Kulkarni K, et al. The frequency with which empiric amounts of radioiodine “over” and “under” treat patients with metastatic well-differentiated thyroid cancer. J Nucl Med 2005; 46:129P

    Google Scholar 

  29. Wang SJ, Liu TJ. Use of fractionated doses of iodine-131 for ablation of thyroid remnants. Chinese Med J 2002; 65:336–340.

    Google Scholar 

  30. Hung Gu, Tu ST, Wu IS, et al. Comparison of the effectiveness between a single low dose and fractionated doses of radioiodine in ablation of post-operative thyroid remnants. Jpn J Clin Onc 2004; 34:469–471.

    Article  Google Scholar 

  31. Thomas SR, Maxon HR, Kereiakes JG, Saenger EL. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology 1997; 122:731–737.

    Google Scholar 

  32. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171–182.

    PubMed  CAS  Google Scholar 

  33. DeGroot L, Reily M. Comparison of 30-and 50-mCi of doses of iodine-131 for thyroid ablation. Annals Intern Med 1992; 96:51–53.

    Google Scholar 

  34. Kuni CC, Klingensmith WC. Failure of low doses of I-131 to ablate residual thyroid tissue following surgery for thyroid cancer. Radiology 1980; 137:773–774.

    PubMed  CAS  Google Scholar 

  35. Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of I-131 for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77:2574–2580.

    Article  PubMed  CAS  Google Scholar 

  36. Bal CS, Kumar A, Pant GS. Radioiodine doses of 25 to 50 mCi are equally effective for thyroid remnant ablation in patients with thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:1666–1673.

    Article  PubMed  CAS  Google Scholar 

  37. Doi SAR, Woodhouse NJY. Ablation of the thyroid remnant and 131 dose in differentiated thyroid cancer. Clin Endocrinol 2000; 52:765–773.

    Article  CAS  Google Scholar 

  38. Samuel AM, Rajashekharrao B. Radioiodine therapy for welldifferentiated thyroid cancer: A quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994; 35:1944–1950.

    PubMed  CAS  Google Scholar 

  39. Sisson JC. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected. J Nucl Med 1983; 24:743–745.

    PubMed  CAS  Google Scholar 

  40. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well differentiated thyroid cancer-a quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 1992; 33:1132–1136.

    PubMed  Google Scholar 

  41. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937–941.

    Article  PubMed  CAS  Google Scholar 

  42. Hodgson DC, Brierley JD, Tsang RW, Panzarella T. Prescribing 131-I iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol 1998; 47:325–330.

    Article  PubMed  CAS  Google Scholar 

  43. Comtois R, Theriault C, Del Vecchio P. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 1993; 34:1927–1930.

    PubMed  CAS  Google Scholar 

  44. Leung SF, Law MWM, Ho SKW. Efficacy of low-dose iodine-131 ablation of postoperative thyroid remnants: a study of 69 cases. Br J Radiol 1992; 65:905–909.

    PubMed  CAS  Google Scholar 

  45. Logue JP, Tang RW, Brierley JD, et al. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. Br J Radiol 1994; 67:1127–1131.

    PubMed  CAS  Google Scholar 

  46. Ramacciotti C, Pretorius HT, Line B, et al. Ablation of non-malignant thyroid remnants with low doses of radioactive iodine: concise communication. J Nucl Med 1982; 23:483–489.

    PubMed  CAS  Google Scholar 

  47. Verkooijen RB, Stokkel MPM, Smit JWA, et al. Radioactive I-131 in differentiated thyroid cancer: a retrospective analysis of an uptakerelated ablation strategy. Eur J Nucl Med 2004; 31:499–506.

    Article  CAS  Google Scholar 

  48. Reynolds JC. Comparison of I-131absorbed radiation doses in children and adults; a tool for estimating therapeutic I-131 doses in children. In Robbins J, editor. Treatment of Thyroid Cancer in Children. Springfield, VA: US Department of Commerce Technology Administration, National Technical Information Service, 1994:127–135.

    Google Scholar 

  49. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 1999; 43:313–323.

    PubMed  CAS  Google Scholar 

  50. Pacini F. Options for ablating thyroid remnants. Vancouver, Canada: Presentation at the 2004 American Thyroid Association Meeting, 2004

    Google Scholar 

  51. Society of nuclear medicine procedure guideline for therapy of thyroid disease with iodine-131 (sodium iodide). Procedure Guidelines Manual, Society of Nuclear Medicine, 2002:159–164.

    Google Scholar 

  52. Meier DA, Brill DR, Becker DV, et al. Procedure guideline for therapy of thyroid disease with I-131. J Nucl Med 2002; 43:856–861.

    PubMed  CAS  Google Scholar 

  53. EANM procedure guidelines for therapy with iodine-131. Eur J Nucl Med 2003; 30:BP27–BP31.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Washington Hospital Center, Washington, DC

    Douglas Van Nostrand MD, FACP, FACNP (Director)

Authors
  1. Douglas Van Nostrand MD, FACP, FACNP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Washington Hospital Center, Washington, DC

    Leonard Wartofsky MD, MPH, MACP  & Douglas Van Nostrand MD, FACP, FACNP  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Van Nostrand, D. (2006). Prescribed Activity for Radioiodine Ablation. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-995-0_26

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-462-3

  • Online ISBN: 978-1-59259-995-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation